eMeasures for Public Comment

113 eMeasures are open for a 60-day Public and Member comment period through April 1 at 6:00 pm ET.

NQF seeks:

- · General comments on eMeasures;
- Comments on eMeasures components (i.e., denominator, codelist, etc.); and
- Comments on potential substantive changes to the intent and meaning of the originally endorsed measure during the retooling process.

Comments regarding potential substantive changes will be reviewed by the eMeasure Format Review Panel. In 2010, the Panel completed evaluation 16 eMeasures for substantive change. These measures are marked with an asterisk (*). The Review Panel will evaluate the 97 remaining eMeasures in 2011.

NQF #:	0001
MEASURE TITLE:	Asthma Assessment
MEASURE DESCRIPTION:	Percentage of patients aged 5 through 40 years with a diagnosis of asthma who were evaluated during at least one office visit within 12 months for the frequency (numeric) of daytime and nocturnal asthma symptoms.
NQF #:	0002
MEASURE TITLE:	Appropriate Testing for Children with Pharyngitis
MEASSRE IIIEE.	Appropriate resting for estimated with a harylights
MEASURE DESCRIPTION:	The percentage of children 2-18 years of age who were diagnosed with Pharyngitis, dispensed an antibiotic and received a group A streptococcus (strep) test for the episode.
NQF #:	0004
MEASURE TITLE:	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement
MEASURE DESCRIPTION:	The percentage of adolescent and adult patients with a new episode of alcohol and other drug (AOD) dependence who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization within 14 days of the diagnosis and who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initial visit.
NQF #:	0012
MEASURE TITLE:	Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)
MEASURE DESCRIPTION:	Percentage of patients, regardless of age, who gave birth during a 12-month period who
	were screened for HIV infection during the first or second prenatal visit.
NQF #:	0013
MEASURE TITLE:	Hypertension: Blood Pressure Measurement
MEASURE DESCRIPTION:	Percentage of patient visits for patients aged 18 years and older with a diagnosis of
	hypertension with blood pressure (BP) recorded.

NQF #:	0014
MEASURE TITLE:	Prenatal Care: Anti-D Immune Globulin
MEASURE DESCRIPTION:	Percentage of D(Rh) negative, unsensitized patients, regardless of age, who gave birth
	during a 12-month period who received anti-D immune globulin at 26-30 weeks
	gestation.
NQF #:	0018
MEASURE TITLE:	Controlling High Blood Pressure
MEASURE DESCRIPTION:	The percentage of patients 18-85 years of age who had a diagnosis of hypertension and
	whose BP was adequately controlled during the measurement year.
	*Reviewed for substantive changes by the eMeasure Format Review Panel in 2010
NOT #	0000
NQF #:	0022
MEASURE TITLE:	Drugs to be avoided in the elderly:
	a. Patients who receive at least one drug to be avoided, b. Patients who receive at least two different drugs to be avoided
MEASURE DESCRIPTION:	Percentage of patients ages 65 years and older who received at least one drug to be
MEAGGRE BEGGRIF HOR.	avoided in the elderly in the measurement year. Percentage of patients 65 years of age
	and older who received at least two different drugs to be avoided in the elderly in the
	measurement year.
NQF #:	0024
MEASURE TITLE:	Weight Assessment and Counseling for Children and Adolescents
MEASURE DESCRIPTION:	The percentage of patients 2-17 years of age who had an outpatient visit with a PCP or
	OB/GYN and who had evidence of BMI percentile documentation, counseling for
	nutrition and counseling for physical activity during the measurement year.
NQF#:	0007
MEASURE TITLE:	0027 Smoking and Tobacco Use Cessation, Medical assistance:
WEASORE TITLE.	a. Advising Smokers and Tobacco Users to Quit,
	b. Discussing Smoking and Tobacco Use Cessation Medications,
	c. Discussing Smoking and Tobacco Use Cessation Strategies
MEASURE DESCRIPTION:	The percentage of patients 18 years of age and older who were current smokers or
	tobacco users, who were seen by a practitioner during the measurement year and who
	received advice to quit smoking or tobacco use or whose practitioner recommended or
	discussed smoking or tobacco use cessation medications, methods or strategies.
	*Reviewed for substantive changes by the eMeasure Format Review Panel in 2010
NQF #:	0028a
MEASURE TITLE:	Preventive Care and Screening Measure Pair:
MEASURE DESCRIPTION	a. Tobacco Use Assessment
MEASURE DESCRIPTION:	Percentage of patients aged 18 years or older who have been seen for at least 2 office
	visits, who were queried about tobacco use one or more times within 24 months. *Reviewed for substantive changes by the eMeasure Format Review Panel in 2010
	The viewed for Substantive Changes by the elvicasure i Offiat Neview Failel III 2010

NQF #:	0041
MEASURE TITLE:	Preventive Care and Screening: Influenza Immunization for Patients >= 50 Years Old
MEASURE DESCRIPTION:	Percentage of patients aged 50 years and older who received an influenza
	immunization during the flu season (September through February).
NQF #:	0043
MEASURE TITLE:	Pneumonia Vaccination Status for Older Adults
MEASURE DESCRIPTION:	The percentage of patients 65 years of age and older who have ever received a
	pneumococcal vaccine.
NOT #	*Reviewed for substantive changes by the eMeasure Format Review Panel in 2010
NQF #: MEASURE TITLE:	0045 Osteoporosis: Communication with the Physician Managing Ongoing Care Post-
MEASURE IIILE.	Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older
MEASURE DESCRIPTION:	Percentage of patients aged 50 years and older treated for a hip, spine, or distal radial
	fracture with documentation of communication with the physician managing the patient's
	on-going care that a fracture occurred and that the patient was or should be tested or
	treated for osteoporosis.
NQF #:	0046
MEASURE TITLE:	Osteoporosis: Screening or Therapy for Osteoporosis for Women Aged 65 Years
	and Older
MEASURE DESCRIPTION:	Percentage of female patients aged 65 years and older who have a central dual-energy
	X-ray absorptiometry measurement ordered or performed at least once since age 60 or
	pharmacologic therapy prescribed within 12 months.
NQF #:	0047
MEASURE TITLE:	Asthma Pharmacologic Therapy
MEASURE DESCRIPTION:	Percentage of patients aged 5 through 40 years with a diagnosis of mild, moderate, or
	severe persistent asthma who were prescribed either the preferred long-term control
	medication (inhaled corticosteroid) or an acceptable alternative treatment.
NQF #:	0048
MEASURE TITLE:	Osteoporosis: Management Following Fracture of Hip, Spine or Distal radius for
	Men and Women Aged 50 Years and Older
MEASURE DESCRIPTION:	Percentage of patients aged 50 years or older with fracture of the hip, spine or distal
	radius that had a central dual-energy X-ray absorptiometry measurement ordered or
	performed or pharmacologic therapy prescribed.
NQF#:	0049
MEASURE TITLE:	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and
	Older
MEASURE DESCRIPTION:	Percentage of patients aged 50 years and older with a diagnosis of osteoporosis who
	were prescribed pharmacologic therapy within 12 months.

eMeasures for Public Comment

NQF #:	0051

MEASURE TITLE: Osteoarthritis: assessment for use of anti-inflammatory or analgesic over-the-

counter (OTC) medications

MEASURE DESCRIPTION: Percentage of patient visits for patients aged 21 years and older with a diagnosis of OA

with an assessment for use of anti-inflammatory or analgesic OTC medications.

NQF #: 0052

MEASURE TITLE: Low Back Pain: Use of Imaging Studies

MEASURE DESCRIPTION: The percentage of patients with a primary diagnosis of low back pain who did not have

an imaging study (plain X-ray, MRI, CT scan) within 28 days of diagnosis.

NQF #: 0055

MEASURE TITLE: Diabetes: Eye Exam

MEASURE DESCRIPTION: The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had

a retinal or dilated eye exam or a negative retinal exam (no evidence of retinopathy) by

an eye care professional.

NQF #: 0056

MEASURE TITLE: Diabetes: Foot Exam

MEASURE DESCRIPTION: The percentage of patients aged 18-75 years with diabetes (type 1 or type 2) who had a

foot exam (visual inspection, sensory exam with monofilament, or pulse exam).

NQF #: 0059

MEASURE TITLE: Diabetes: HbA1c Poor Control

MEASURE DESCRIPTION: The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had

HbA1c > 9.0%.

*Reviewed for substantive changes by the eMeasure Format Review Panel in 2010

NQF #: 0060

MEASURE TITLE: Hemoglobin A1c Test for Pediatric Patients

MEASURE DESCRIPTION: Percentage of pediatric patients with diabetes with a HbA1c test in a 12-month

measurement period.

NQF #: 0061

MEASURE TITLE: Diabetes: Blood Pressure Management

MEASURE DESCRIPTION: The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had

BP < 140/90 mmHg.

*Reviewed for substantive changes by the eMeasure Format Review Panel in 2010

NQF #: 0062

MEASURE TITLE: Diabetes: Urine Screening

MEASURE DESCRIPTION: The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had

a nephropathy screening test or evidence of nephropathy.

NQF #: 0064

MEASURE TITLE: Diabetes: LDL Management & Control

MEASURE DESCRIPTION: The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had

LDL-C <100ma/dL.

*Reviewed for substantive changes by the eMeasure Format Review Panel in 2010

NQF #:	0066
MEASURE TITLE:	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor
	or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and
	Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of CAD who also have
	diabetes and/or left ventricular systolic dysfunction (LVSD) who were prescribed ACE
	Inhibitor or ARB therapy.
NQF #:	0067
MEASURE TITLE:	Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients
	with CAD
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of CAD who were
	prescribed oral antiplatelet therapy.
NQF#:	0068
MEASURE TITLE:	Ischemic Vascular Disease (IVD): Use of Aspirin or another Antithrombotic
MEASURE DESCRIPTION:	The percentage of patients 18 years of age and older who were discharged alive for
	acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous
	transluminal coronary angioplasty (PTCA) from January 1 - November 1 of the year
	prior to the measurement year, or who had a diagnosis of ischemic vascular disease
	(IVD) during the measurement year and the year prior to the measurement year and
	who had documentation of use of aspirin or another antithrombotic during the
	measurement year. *Reviewed for substantive changes by the eMeasure Format Review Panel in 2010
	Reviewed for Substantive Changes by the evileasure Porthal Review Parier in 2010
NQF #:	0069
MEASURE TITLE:	Treatment for Children with Upper Respiratory Infection (URI): Avoidance of
	Inappropriate Use
MEASURE DESCRIPTION:	Percentage of children who were given a diagnosis of URI and were not dispensed an
	antibiotic prescription on or three days after the episode date.
NQF #:	0070
MEASURE TITLE:	Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior
	Myocardial Infarction (MI)
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of CAD and prior MI
	who were prescribed beta-blocker therapy.
	*Reviewed for substantive changes by the eMeasure Format Review Panel in 2010
NQF #:	0073
MEASURE TITLE:	Ischemic Vascular Disease (IVD): Blood Pressure Management
MEASURE DESCRIPTION:	The percentage of patients 18 years of age and older who were discharged alive for
	acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous
	transluminal coronary angioplasty (PTCA) from January 1 st to November 1st of the year
	prior to the measurement year, or who had a diagnosis of ischemic vascular disease
	(IVD) during the measurement year and the year prior to the measurement year and
	whose most recent blood pressure is in control (<140/90 mmHg).

NQF #:	0074
MEASURE TITLE:	Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of CAD who were
	prescribed a lipid-lowering therapy (based on current ACC/AHA guidelines).
	procention a lipid remaining metapy (cased on carrein receive in a galacimics).
NQF #:	0075
MEASURE TITLE:	Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
MEASURE DESCRIPTION:	The percentage of patients 18 years of age and older who were discharged alive for
	acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous
	transluminal coronary angioplasty (PTCA) from January 1st to November 1st of the year
	prior to the measurement year, or who had a diagnosis of ischemic vascular disease
	(IVD) during the measurement year and the year prior to the measurement year and
	who had a complete lipid profile performed during the measurement year and whose
	LDL-C was < 100 mg/dL.
	*Reviewed for substantive changes by the eMeasure Format Review Panel in 2010
NQF #:	0081
MEASURE TITLE:	Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or
WEASORE TITLE.	Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic
	Dysfunction (LVSD)
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of heart failure and
	LVSD (LVEF < 40%) who were prescribed ACE inhibitor or ARB therapy.
	*Reviewed for substantive changes by the eMeasure Format Review Panel in 2010
NQF #:	0083
MEASURE TITLE:	Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction
	(LVSD)
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of heart failure who
	also have LVSD (LVEF < 40%) and who were prescribed beta-blocker therapy.
NQF #:	0084
MEASURE TITLE:	Heart Failure (HF) : Warfarin Therapy Patients with Atrial Fibrillation
MEASURE DESCRIPTION:	Percentage of all patients aged 18 and older with a diagnosis of heart failure and
	paroxysmal or chronic atrial fibrillation who were prescribed warfarin therapy.
	, , , , , , , , , , , , , , , , , , , ,
NQF #:	0086
MEASURE TITLE:	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of POAG who have
	been seen for at least 2 office visits, who have an optic nerve head evaluation during
	one or more office visits within 12 months.
NOT#	0000
NQF #:	0088
MEASURE TITLE:	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy
MEASURE BESCRIPTION.	who had a dilated macular or fundus exam performed which included documentation of
	the level of severity of retinopathy and the presence or absence of macular edema
	during one or more office visits within 12 months.

NQF #:	0089
MEASURE TITLE:	Diabetic Retinopathy: Communication with the Physician Managing Ongoing
	Diabetes Care
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy
	who had a dilated macular or fundus exam performed with documented communication
	to the physician who manages the on-going care of the patient with diabetes mellitus
	regarding the findings of the macular or fundus exam at least once within 12 months.
NQF #:	0097
MEASURE TITLE:	Medication Reconciliation
MEASURE DESCRIPTION:	Percentage of patients aged 65 years and older discharged from any inpatient facility
	(e.g. hospital, skilled nursing facility, or rehabilitation facility) and seen within 60 days
	following discharge in the office by the physician providing on-going care who had a
	reconciliation of the discharge medications with the current medication list in the medical
	record documented.
NQF #:	0102
MEASURE TITLE:	
MEASURE DESCRIPTION:	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy Percentage of symptomatic patients aged 18 years and older with a diagnosis of COPD
WEASURE DESCRIPTION.	who were prescribed an inhaled bronchodilator.
	who were prescribed air irinaled bronchodilator.
NQF #:	0103
MEASURE TITLE:	Major Depressive Disorder (MDD): Diagnostic Evaluation
MEASURE DESCRIPTION:	Percentage of patients with a diagnosis of major depressive disorder who met the DSM-
	IV™ criteria during the visit in which the new diagnosis or recurrent episode was
	identified.
NQF #:	0104
MEASURE TITLE:	Major Depressive Disorder (MDD): Suicide Risk Assessment
MEASURE DESCRIPTION:	Percentage of patients who had a suicide risk assessment completed at each visit.
NQF #:	0105
MEASURE TITLE:	Anti-depressant medication management:
	(a) Effective Acute Phase Treatment,
MEASURE DESCRIPTION.	(b)Effective Continuation Phase Treatment
MEASURE DESCRIPTION:	The percentage of patients 18 years of age and older who were diagnosed with a new episode of major depression, treated with antidepressant medication, and who remained
	on an antidepressant medication treatment.
	on an anticepressant medication treatment.
NQF #:	0106
MEASURE TITLE:	Diagnosis of attention deficit hyperactivity disorder (ADHD) in primary care for
	school age children and adolescents
MEASURE DESCRIPTION:	Percentage of patients newly diagnosed with ADHD whose medical record contains
	documentation of DSM-IV-TR or DSM-PC criteria.

NQF #:	0107
MEASURE TITLE:	Management of attention deficit hyperactivity disorder (ADHD) in primary care for school age children and adolescents
MEASURE DESCRIPTION:	Percentage of patients treated psychostimulant with medication for the diagnosis of ADHD whose medical record contains documentation of a follow-up visit at least twice a year.
NQF #:	0108
MEASURE TITLE:	ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication
MEASURE DESCRIPTION:	a. Initiation Phase: Percentage of children 6 - 12 years of age as of the Index Prescription Episode Start Date with an ambulatory prescription dispensed for and ADHD medication and who had one follow-up visit with a practitioner with prescribing authority during the 30-Day Initiation Phase. b. Continuation and Maintenance (C&M) Phase: Percentage of children 6 - 12 years of age as of the Index Prescription Episode Start Date with an ambulatory prescription dispensed for ADHD medication who remained on the medication for at least 210 days and who in addition to the visit in the Initiation Phase had at least two additional follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ends.
NQF #:	0112
MEASURE TITLE:	Bipolar Disorder: Monitoring change in level-of-functioning
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with an initial diagnosis or new episode/presentation of bipolar disorder.
NQF #:	0132
MEASURE TITLE:	Aspirin at Arrival
MEASURE DESCRIPTION:	Acute myocardial infarction (AMI) patients who received aspirin within 24 hours before or after hospital arrival.
NQF #:	0137
MEASURE TITLE:	ACEI or ARB for LVSD
MEASURE DESCRIPTION:	Acute myocardial infarction (AMI) patients with left ventricular systolic dysfunction (LVSD) who are prescribed an ACEI or ARB at hospital discharge. For purposes of this measure, LVSD is defined as chart documentation of a left ventricular ejection fraction (LVEF) less than 40% or a narrative description of left ventricular systolic (LVS) function consistent with moderate or severe systolic dysfunction.
NQF #:	0138
MEASURE TITLE:	Urinary catheter-associated urinary tract infection for intensive care unit (ICU) patients
MEASURE DESCRIPTION:	Standardized Infection Ration (SIR) of healthcare-associated, catheter-associated urinary tract infections (CAUTI) among patients in intensive care units (ICUs), excluding patients in neonatal ICUs (NICUs).

NQF #:	0139
MEASURE TITLE:	Central line catheter-associated blood stream infection rate for ICU and high-risk nursery (HRN) patients
MEASURE DESCRIPTION:	Standardized Infection Ration (SIR) of healthcare-associated, central line-associated
	bloodstream infections (CLABSI) among patients in intensive care units (ICUs) and
	Neonatal Intensive Care Units (NICUs).
NQF #:	0142
MEASURE TITLE:	Aspirin Prescribed at Discharge
MEASURE DESCRIPTION:	Acute myocardial infarction (AMI) patients who are prescribed aspirin at hospital
	discharge.
NOT #	04.47
NQF#:	0147
MEASURE TITLE:	Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients
MEASURE DESCRIPTION:	Immunocompetent Patients Immunocompetent patients with Community-Acquired Pneumonia who receive an initial
WEASURE DESCRIPTION.	antibiotic regimen during the first 24 hours that is consistent with current guidelines.
	and blodic regimen during the first 24 hours that is consistent with current guidelines.
NQF #:	0148
MEASURE TITLE:	Blood Cultures Performed in the Emergency Department Prior to Initial Antibiotic
	Received in Hospital
MEASURE DESCRIPTION:	Pneumonia patients whose initial emergency room blood culture specimen was
	collected prior to first hospital dose of antibiotics. This measure focuses on the
	treatment provided to Emergency Department patients prior to admission orders.
NQF #:	0151
MEASURE TITLE:	Initial Antibiotic Received Within 6 Hours of Hospital Arrival
MEASURE DESCRIPTION:	Pneumonia patients who receive their first dose of antibiotics within 6 hours after arrival
	at the hospital.
NOT#	0400
NQF #: MEASURE TITLE:	0160
MEASURE DESCRIPTION:	Beta-Blocker Prescribed at Discharge Acute myocardial infarction (AMI) patients who are prescribed a beta-blocker at hospital
MEASURE DESCRIPTION.	discharge.
	discharge.
NQF #:	0163
MEASURE TITLE:	Primary PCI Received Within 90 Minutes of Hospital Arrival
MEASURE DESCRIPTION:	Acute myocardial infarction (AMI) patients with ST-segment elevation or LBBB on the
	ECG closest to arrival time receiving primary PCI during the hospital stay with a time
	from hospital arrival to PCI of 90 minutes or less.
	·
NQF #:	0164
	Fibringlytic Thereny Deceived Within 20 Minutes of Heapital Arrival
MEASURE TITLE:	Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival
MEASURE TITLE: MEASURE DESCRIPTION:	Acute myocardial infarction (AMI) patients with ST-segment elevation or LBBB on the

NOT "	0000
NQF #:	0239
MEASURE TITLE:	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (when indicated in ALL patients)
MEASURE DESCRIPTION:	Patient Age: All patients age 18 years and older. Procedures: surgical procedures for which VTE prophylaxis is indicated in all patients who had an order for LMWH, LDUH, adjusted-dose warfarin, fondaparinux or mechanical prophylaxis given within 24 hours prior to incision time or 24 hours after surgery end time.
NQF #:	0241
MEASURE TITLE:	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke or transient ischemic attack (TIA) with documented permanent, persistent, or paroxysmal atrial fibrillation who were prescribed an anticoagulant at discharge.
NQF #:	0246
MEASURE TITLE:	Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic
	Resonance Imaging (MRI) Reports
MEASURE DESCRIPTION:	Percentage of final reports for CT or MRI studies of the brain performed either: In the hospital within 24 hours of arrival, OR in an outpatient imaging center to confirm initial
	diagnosis of stroke, TIA or intracranial hemorrhage. For patients aged 18 years and
	older with either a diagnosis of ischemic stroke or transient ischemic attack (TIA) or
	intracranial hemorrhage OR at least one documented symptom consistent with ischemic
	stroke, TIA or intracranial hemorrhage that includes documentation of the presence or
	absence of each of the following: hemorrhage and mass lesion and acute infarction.
NQF #:	0268
MEASURE TITLE:	Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second
	Generation Cephalosporin
MEASURE DESCRIPTION:	Percentage of surgical patients aged 18 years and older undergoing procedures with
	the indications for a first OR second generation cephalosporin prophylactic antibiotic who had an order for cefazolin OR cefuroxime for antimicrobial prophylaxis.
NQF#:	0270
MEASURE TITLE:	Perioperative Care: Timing of Prophylactic Antibiotics - Ordering Physician
MEASURE DESCRIPTION:	Percentage of surgical patients aged 18 years and older undergoing procedures with
	the indications for prophylactic parenteral antibiotics who have an order for an antibiotic
	to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to the
	surgical incision (or start of procedure when no incision is required).
NQF #:	0271
MEASURE TITLE:	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)
MEASURE DESCRIPTION:	Percentage of non-cardiac surgical patients aged 18 years and older undergoing procedures with the indications for prophylactic antibiotics AND who received a
	prophylactic antibiotic, who have an order for discontinuation of prophylactic antibiotics within 24 hours of surgical end time.

NQF #:	0298
MEASURE TITLE:	Central Line Bundle Compliance
MEASURE DESCRIPTION:	The percentage of intensive care patients in the included ICUs with central lines for who
	all five elements of the central line "bundle" are documented on the daily goals sheet,
	central line checklist, patient's medical record, or other documentation tool.
NQF#:	0300
MEASURE TITLE:	Cardiac Surgery Patients With Controlled 6 A.M. Postoperative Blood Glucose
MEASURE DESCRIPTION:	Cardiac surgery patients with controlled 6 A.M. blood glucose (less than or equal to 200
	mg/dL) on postoperative day one (POD 1) and postoperative day two (POD 2) with
NQF #:	Anesthesia End Date being postoperative day zero (POD 0). 0302
MEASURE TITLE:	Ventilator Bundle
MEASURE DESCRIPTION:	The percentage of intensive care patients on mechanical ventilation for whom all five
WEASORE DESCRIPTION.	elements of the ventilator "bundle" are implemented and documented.
	ciernents of the ventilator bundle are implemented and documented.
NQF #:	0321
MEASURE TITLE:	End Stage Renal Disease (ESRD): Plan of Care for Inadequate Peritoneal Dialysis
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of ESRD receiving
	peritoneal dialysis who have a Kt/V>=1.7 OR patients who have a Kt/V<1.7 with a
	documented plan of care 3 times a year (every 4 months) during the 12 month reporting
	period.
NQF #:	0323
NQF #: MEASURE TITLE:	End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in
MEASURE TITLE:	End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients
	End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which
MEASURE TITLE:	End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis
MEASURE TITLE:	End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which
MEASURE TITLE: MEASURE DESCRIPTION:	End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care.
MEASURE TITLE: MEASURE DESCRIPTION: NQF #:	End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care.
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care. 0329 All Cause Readmission Index (risk adjusted)
MEASURE TITLE: MEASURE DESCRIPTION: NQF #:	End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care.
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION:	End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care. 0329 All Cause Readmission Index (risk adjusted) 30-day Readmission Index for Non-Maternity and Non-Pediatric Discharges.
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #:	End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care. 0329 All Cause Readmission Index (risk adjusted)
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION:	End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care. 0329 All Cause Readmission Index (risk adjusted) 30-day Readmission Index for Non-Maternity and Non-Pediatric Discharges. 0341 PICU Pain Assessment
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care. 0329 All Cause Readmission Index (risk adjusted) 30-day Readmission Index for Non-Maternity and Non-Pediatric Discharges.
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care. 0329 All Cause Readmission Index (risk adjusted) 30-day Readmission Index for Non-Maternity and Non-Pediatric Discharges. 0341 PICU Pain Assessment
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE TITLE:	End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care. 0329 All Cause Readmission Index (risk adjusted) 30-day Readmission Index for Non-Maternity and Non-Pediatric Discharges. 0341 PICU Pain Assessment Percentage of PICU patients receiving pain assessment on admission.
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #:	End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care. 0329 All Cause Readmission Index (risk adjusted) 30-day Readmission Index for Non-Maternity and Non-Pediatric Discharges. 0341 PICU Pain Assessment Percentage of PICU patients receiving pain assessment on admission.
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE TITLE: MEASURE TITLE: MEASURE TITLE: MEASURE DESCRIPTION:	End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care. 0329 All Cause Readmission Index (risk adjusted) 30-day Readmission Index for Non-Maternity and Non-Pediatric Discharges. 0341 PICU Pain Assessment Percentage of PICU patients receiving pain assessment on admission. 0342 PICU Periodic Pain Assessment Percentage of PICU patients receiving periodic pain assessment.
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE DESCRIPTION:	End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care. 0329 All Cause Readmission Index (risk adjusted) 30-day Readmission Index for Non-Maternity and Non-Pediatric Discharges. 0341 PICU Pain Assessment Percentage of PICU patients receiving pain assessment on admission. 0342 PICU Periodic Pain Assessment Percentage of PICU patients receiving periodic pain assessment.
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE TITLE: MEASURE DESCRIPTION:	End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care. 0329 All Cause Readmission Index (risk adjusted) 30-day Readmission Index for Non-Maternity and Non-Pediatric Discharges. 0341 PICU Pain Assessment Percentage of PICU patients receiving pain assessment on admission. 0342 PICU Periodic Pain Assessment Percentage of PICU patients receiving periodic pain assessment. 0348 latrogenic Pneumothorax in Non-Neonates (risk adjusted) (PDI5)
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE DESCRIPTION: NQF #:	End Stage Renal Disease (ESRD): Plan of Care of Inadequate Hemodialysis in ESRD Patients Percentage of patient calendar months during the 12 month reporting period in which patients aged 18 years and older with a diagnosis of ESRD and receiving hemodialysis have a Kt/V>=1.2 OR have a Kt/V<1.2 with a documented plan of care. 0329 All Cause Readmission Index (risk adjusted) 30-day Readmission Index for Non-Maternity and Non-Pediatric Discharges. 0341 PICU Pain Assessment Percentage of PICU patients receiving pain assessment on admission. 0342 PICU Periodic Pain Assessment Percentage of PICU patients receiving periodic pain assessment.

NQF#:	0356
MEASURE TITLE:	Blood Cultures Performed Within 24 Hours Prior to or 24 Hours After Hospital
menoske mee.	Arrival for Patients Who Were Transferred or Admitted to the ICU Within 24 Hours
	of Hospital Arrival
MEASURE DESCRIPTION:	Pneumonia patients transferred or admitted to the ICU within 24 hours of hospital
	arrival, who had blood cultures performed within 24 hours prior to or the day prior to
	arrival, the day of arrival, or within 24 hours after arrival to the hospital.
NQF #:	0362
MEASURE TITLE:	Foreign Body left after procedure (PDI3)
MEASURE DESCRIPTION:	Discharges with foreign body accidently left in during procedure per 1000 discharges.
NQF #:	0385
MEASURE TITLE:	Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with Stage IIIA through IIIC colon
	cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy,
	or have previously received adjuvant chemotherapy within the 12-month reporting
	period.
NQF#:	0387
MEASURE TITLE:	Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen
WEASURE TITLE.	Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
MEASURE DESCRIPTION:	Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER
III Z NOONE DEGONII HON	or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI)
	during the 12-month reporting period.
	3 :=
NQF #:	0389
MEASURE TITLE:	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk
	Prostate Cancer Patients
MEASURE DESCRIPTION:	Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk
	of recurrence receiving interstitial prostate brachytherapy, OR external beam
	radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not
	have a bone scan performed at any time since diagnosis of prostate cancer.
NQF #:	0207
MEASURE TITLE:	0397
MEASURE TITLE: MEASURE DESCRIPTION:	Hepatitis C: Antiviral Treatment Prescribed Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C
WEASURE DESCRIPTION.	who were prescribed peginterferon and ribavirin therapy within the 12 month reporting
	period.
	ponod.
NQF#:	0399
MEASURE TITLE:	Hepatitis C: Hepatitis A Vaccination in Patients with HCV
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who
	have received at least one injection of hepatitis A vaccine, or who have documented
	immunity to hepatitis A.
	•

NQF #:	0400
MEASURE TITLE:	Hepatitis C: Hepatitis B Vaccination in Patients with HCV
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who
	have received at least one injection of hepatitis B vaccine, or who have documented
	immunity to hepatitis B.
NQF #:	0401
MEASURE TITLE:	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who
	were counseled regarding the risks of alcohol consumption at least once within the 12
	month reporting period.
NQF #:	0416
MEASURE TITLE:	Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a diagnosis of diabetes mellitus
	who were evaluated for proper footwear and sizing.
NQF#:	0421
MEASURE TITLE:	Adult Weight Screening and Follow-Up
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older with a calculated BMI in the past six
	months or during the current visit documented in the medical record AND if the most
	recent BMI is outside parameters, a follow-up plan is documented.
	*Reviewed for substantive changes by the eMeasure Format Review Panel in 2010
NQF#:	0453
NQF #: MEASURE TITLE:	Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2
MEASURE TITLE:	Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero
	Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2
MEASURE TITLE: MEASURE DESCRIPTION:	Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero.
MEASURE TITLE: MEASURE DESCRIPTION: NQF #:	Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero. 0471
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero. 0471 Cesarean Rate for Low-Risk Birth Women
MEASURE TITLE: MEASURE DESCRIPTION: NQF #:	Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero. 0471 Cesarean Rate for Low-Risk Birth Women Cesarean Rate for low-risk first birth women (aka NTSV CS rate: nulliparous, term,
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero. 0471 Cesarean Rate for Low-Risk Birth Women Cesarean Rate for low-risk first birth women (aka NTSV CS rate: nulliparous, term, singleton, vertex) identifies the portion of cesarean births that has the most variation
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero. 0471 Cesarean Rate for Low-Risk Birth Women Cesarean Rate for low-risk first birth women (aka NTSV CS rate: nulliparous, term, singleton, vertex) identifies the portion of cesarean births that has the most variation among practitioners, hospitals, regions and states. Unlike other cesarean measures, it
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero. 0471 Cesarean Rate for Low-Risk Birth Women Cesarean Rate for low-risk first birth women (aka NTSV CS rate: nulliparous, term, singleton, vertex) identifies the portion of cesarean births that has the most variation among practitioners, hospitals, regions and states. Unlike other cesarean measures, it focuses attention on the proportion of cesarean births that is affected by elective
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero. 0471 Cesarean Rate for Low-Risk Birth Women Cesarean Rate for low-risk first birth women (aka NTSV CS rate: nulliparous, term, singleton, vertex) identifies the portion of cesarean births that has the most variation among practitioners, hospitals, regions and states. Unlike other cesarean measures, it focuses attention on the proportion of cesarean births that is affected by elective medical practices such as induction and early labor admission. Furthermore, the
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero. 0471 Cesarean Rate for Low-Risk Birth Women Cesarean Rate for low-risk first birth women (aka NTSV CS rate: nulliparous, term, singleton, vertex) identifies the portion of cesarean births that has the most variation among practitioners, hospitals, regions and states. Unlike other cesarean measures, it focuses attention on the proportion of cesarean births that is affected by elective
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero. 0471 Cesarean Rate for Low-Risk Birth Women Cesarean Rate for low-risk first birth women (aka NTSV CS rate: nulliparous, term, singleton, vertex) identifies the portion of cesarean births that has the most variation among practitioners, hospitals, regions and states. Unlike other cesarean measures, it focuses attention on the proportion of cesarean births that is affected by elective medical practices such as induction and early labor admission. Furthermore, the success (or lack thereof) of management of the first labor directly impacts the remainder
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero. O471 Cesarean Rate for Low-Risk Birth Women Cesarean Rate for low-risk first birth women (aka NTSV CS rate: nulliparous, term, singleton, vertex) identifies the portion of cesarean births that has the most variation among practitioners, hospitals, regions and states. Unlike other cesarean measures, it focuses attention on the proportion of cesarean births that is affected by elective medical practices such as induction and early labor admission. Furthermore, the success (or lack thereof) of management of the first labor directly impacts the remainder of the woman's reproductive life especially given the current high rate of repeat cesarean births. This is also the measure used in Healthy Person 2010 (Objective 16.9a, US DHS, 2000) and previously received endorsement from the American College
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero. O471 Cesarean Rate for Low-Risk Birth Women Cesarean Rate for low-risk first birth women (aka NTSV CS rate: nulliparous, term, singleton, vertex) identifies the portion of cesarean births that has the most variation among practitioners, hospitals, regions and states. Unlike other cesarean measures, it focuses attention on the proportion of cesarean births that is affected by elective medical practices such as induction and early labor admission. Furthermore, the success (or lack thereof) of management of the first labor directly impacts the remainder of the woman's reproductive life especially given the current high rate of repeat cesarean births. This is also the measure used in Healthy Person 2010 (Objective 16.9a, US DHS, 2000) and previously received endorsement from the American College of Obstetricians and Gynecologists (American College of Obstetricians and
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero. 0471 Cesarean Rate for Low-Risk Birth Women Cesarean Rate for low-risk first birth women (aka NTSV CS rate: nulliparous, term, singleton, vertex) identifies the portion of cesarean births that has the most variation among practitioners, hospitals, regions and states. Unlike other cesarean measures, it focuses attention on the proportion of cesarean births that is affected by elective medical practices such as induction and early labor admission. Furthermore, the success (or lack thereof) of management of the first labor directly impacts the remainder of the woman's reproductive life especially given the current high rate of repeat cesarean births. This is also the measure used in Healthy Person 2010 (Objective 16.9a, US DHS, 2000) and previously received endorsement from the American College of Obstetricians and Gynecologists (American College of Obstetricians and Gynecologists: Task Force on Cesarean Delivery, 2000). A recent European review of
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero. 0471 Cesarean Rate for Low-Risk Birth Women Cesarean Rate for low-risk first birth women (aka NTSV CS rate: nulliparous, term, singleton, vertex) identifies the portion of cesarean births that has the most variation among practitioners, hospitals, regions and states. Unlike other cesarean measures, it focuses attention on the proportion of cesarean births that is affected by elective medical practices such as induction and early labor admission. Furthermore, the success (or lack thereof) of management of the first labor directly impacts the remainder of the woman's reproductive life especially given the current high rate of repeat cesarean births. This is also the measure used in Healthy Person 2010 (Objective 16.9a, US DHS, 2000) and previously received endorsement from the American College of Obstetricians and Gynecologists (American College of Obstetricians and Gynecologists: Task Force on Cesarean Delivery, 2000). A recent European review of cesarean birth measures also identified that this measure pinpointed the portion of
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero Surgical patients with urinary catheter removed on Postoperative Day 1 or Postoperative Day 2 with day of surgery being day zero. 0471 Cesarean Rate for Low-Risk Birth Women Cesarean Rate for low-risk first birth women (aka NTSV CS rate: nulliparous, term, singleton, vertex) identifies the portion of cesarean births that has the most variation among practitioners, hospitals, regions and states. Unlike other cesarean measures, it focuses attention on the proportion of cesarean births that is affected by elective medical practices such as induction and early labor admission. Furthermore, the success (or lack thereof) of management of the first labor directly impacts the remainder of the woman's reproductive life especially given the current high rate of repeat cesarean births. This is also the measure used in Healthy Person 2010 (Objective 16.9a, US DHS, 2000) and previously received endorsement from the American College of Obstetricians and Gynecologists (American College of Obstetricians and Gynecologists: Task Force on Cesarean Delivery, 2000). A recent European review of

NQF #:	0494
NQF #: MEASURE TITLE:	0484 Proportion of Infants 22 to 20 Wooks Costation Troated with Surfactant who are
WIEASURE TITLE:	Proportion of Infants 22 to 29 Weeks Gestation Treated with Surfactant who are Treated within 2 Hours of Birth
MEASURE DESCRIPTION:	Proportion of infants with gestational age between 22 and 29 completed weeks who
	were treated with surfactant and were treated within two hours of birth.
NQF #:	0496
MEASURE TITLE:	Median Time from ED Arrival to ED Departure for Discharged ED Patients
MEASURE DESCRIPTION:	Median time from emergency department arrival to time of departure from the
	emergency room for patients discharged from the emergency department.
NQF #:	0507
MEASURE TITLE:	Stenosis Measurement in Carotid Imaging Studies
MEASURE DESCRIPTION:	Percentage of final reports for carotid imaging studies (neck MR angiography [MRA],
	neck CT angiography [CTA], neck duplex ultrasound, carotid angiogram) performed that
	include direct or indirect reference to measurements of distal internal carotid diameter
	as the denominator for stenosis measurement.
NQF #:	0508
MEASURE TITLE:	Radiology: Inappropriate Use of "Probably Benign" Assessment Category in
	Mammography Screening
MEASURE DESCRIPTION:	Percentage of final reports for screening mammograms that are classified as "probably
	benign".
NQF #:	
	10510
	0510 Radiology: Exposure Time Reported for Procedures Using Fluoroscopy
MEASURE TITLE:	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy
MEASURE TITLE: MEASURE DESCRIPTION:	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy Percentage of final reports for procedures using fluoroscopy that include documentation
MEASURE TITLE: MEASURE DESCRIPTION: NQF #:	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy Percentage of final reports for procedures using fluoroscopy that include documentation of radiation exposure or exposure time. 0511
MEASURE TITLE: MEASURE DESCRIPTION:	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy Percentage of final reports for procedures using fluoroscopy that include documentation of radiation exposure or exposure time. 0511 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy Percentage of final reports for procedures using fluoroscopy that include documentation of radiation exposure or exposure time. 0511 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy
MEASURE TITLE: MEASURE DESCRIPTION: NQF #:	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy Percentage of final reports for procedures using fluoroscopy that include documentation of radiation exposure or exposure time. 0511 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy Percentage of final reports for all patients, regardless of age, undergoing bone
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy Percentage of final reports for procedures using fluoroscopy that include documentation of radiation exposure or exposure time. 0511 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy Percentage of final reports for all patients, regardless of age, undergoing bone scintigraphy that include physician documentation of correlation with existing relevant
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy Percentage of final reports for procedures using fluoroscopy that include documentation of radiation exposure or exposure time. 0511 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy Percentage of final reports for all patients, regardless of age, undergoing bone
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy Percentage of final reports for procedures using fluoroscopy that include documentation of radiation exposure or exposure time. 0511 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy Percentage of final reports for all patients, regardless of age, undergoing bone scintigraphy that include physician documentation of correlation with existing relevant imaging studies (e.g., X-ray, MRI, CT) that were performed.
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #:	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy Percentage of final reports for procedures using fluoroscopy that include documentation of radiation exposure or exposure time. 0511 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy Percentage of final reports for all patients, regardless of age, undergoing bone scintigraphy that include physician documentation of correlation with existing relevant imaging studies (e.g., X-ray, MRI, CT) that were performed.
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION:	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy Percentage of final reports for procedures using fluoroscopy that include documentation of radiation exposure or exposure time. 0511 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy Percentage of final reports for all patients, regardless of age, undergoing bone scintigraphy that include physician documentation of correlation with existing relevant imaging studies (e.g., X-ray, MRI, CT) that were performed.
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy Percentage of final reports for procedures using fluoroscopy that include documentation of radiation exposure or exposure time. 0511 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy Percentage of final reports for all patients, regardless of age, undergoing bone scintigraphy that include physician documentation of correlation with existing relevant imaging studies (e.g., X-ray, MRI, CT) that were performed. 0513 Use of Contrast: Thorax CT
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE:	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy Percentage of final reports for procedures using fluoroscopy that include documentation of radiation exposure or exposure time. 0511 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy Percentage of final reports for all patients, regardless of age, undergoing bone scintigraphy that include physician documentation of correlation with existing relevant imaging studies (e.g., X-ray, MRI, CT) that were performed. 0513 Use of Contrast: Thorax CT This measure calculates the percentage of thorax studies that are performed with and
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE TITLE: MEASURE TITLE: MEASURE DESCRIPTION:	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy Percentage of final reports for procedures using fluoroscopy that include documentation of radiation exposure or exposure time. 0511 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy Percentage of final reports for all patients, regardless of age, undergoing bone scintigraphy that include physician documentation of correlation with existing relevant imaging studies (e.g., X-ray, MRI, CT) that were performed. 0513 Use of Contrast: Thorax CT This measure calculates the percentage of thorax studies that are performed with and without contrast out of all thorax studies performed (those with contrast, those without contrast, and those with both).
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE TITLE: MEASURE DESCRIPTION:	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy Percentage of final reports for procedures using fluoroscopy that include documentation of radiation exposure or exposure time. 0511 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy Percentage of final reports for all patients, regardless of age, undergoing bone scintigraphy that include physician documentation of correlation with existing relevant imaging studies (e.g., X-ray, MRI, CT) that were performed. 0513 Use of Contrast: Thorax CT This measure calculates the percentage of thorax studies that are performed with and without contrast out of all thorax studies performed (those with contrast, those without contrast, and those with both).
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE TITLE: MEASURE TITLE: MEASURE DESCRIPTION:	Percentage of final reports for procedures using fluoroscopy that include documentation of radiation exposure or exposure time. 0511 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy Percentage of final reports for all patients, regardless of age, undergoing bone scintigraphy that include physician documentation of correlation with existing relevant imaging studies (e.g., X-ray, MRI, CT) that were performed. 0513 Use of Contrast: Thorax CT This measure calculates the percentage of thorax studies that are performed with and without contrast out of all thorax studies performed (those with contrast, those without contrast, and those with both). 0519 Diabetic Foot Care and Patient/Caregiver Education Implemented During Short
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE DESCRIPTION:	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy Percentage of final reports for procedures using fluoroscopy that include documentation of radiation exposure or exposure time. 0511 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy Percentage of final reports for all patients, regardless of age, undergoing bone scintigraphy that include physician documentation of correlation with existing relevant imaging studies (e.g., X-ray, MRI, CT) that were performed. 0513 Use of Contrast: Thorax CT This measure calculates the percentage of thorax studies that are performed with and without contrast out of all thorax studies performed (those with contrast, those without contrast, and those with both). 0519 Diabetic Foot Care and Patient/Caregiver Education Implemented During Short Term Episodes of Care
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE TITLE: MEASURE DESCRIPTION:	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy Percentage of final reports for procedures using fluoroscopy that include documentation of radiation exposure or exposure time. 0511 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy Percentage of final reports for all patients, regardless of age, undergoing bone scintigraphy that include physician documentation of correlation with existing relevant imaging studies (e.g., X-ray, MRI, CT) that were performed. 0513 Use of Contrast: Thorax CT This measure calculates the percentage of thorax studies that are performed with and without contrast out of all thorax studies performed (those with contrast, those without contrast, and those with both). 0519 Diabetic Foot Care and Patient/Caregiver Education Implemented During Short Term Episodes of Care Percentage of short term home health episodes of care during which diabetic foot care
MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE TITLE: MEASURE DESCRIPTION: NQF #: MEASURE DESCRIPTION:	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy Percentage of final reports for procedures using fluoroscopy that include documentation of radiation exposure or exposure time. 0511 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy Percentage of final reports for all patients, regardless of age, undergoing bone scintigraphy that include physician documentation of correlation with existing relevant imaging studies (e.g., X-ray, MRI, CT) that were performed. 0513 Use of Contrast: Thorax CT This measure calculates the percentage of thorax studies that are performed with and without contrast out of all thorax studies performed (those with contrast, those without contrast, and those with both). 0519 Diabetic Foot Care and Patient/Caregiver Education Implemented During Short Term Episodes of Care

eMeasures for Public Comment

NQF #:	0527
MEASURE TITLE:	Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision
MEASURE DESCRIPTION:	Surgical patients with prophylactic antibiotics initiated within one hour prior to surgical
	incision. Patients who received vancomycin or a fluoroquinolone for prophylactic
	antibiotics should have the antibiotics initiated within two hours prior to surgical incision.
	Due to the longer infusion time required for vancomycin or a fluoroquinolone, it is
	acceptable to start these antibiotics within two hours prior to incision time.
NQF #:	0528
MEASURE TITLE:	Prophylactic Antibiotic Selection for Surgical Patients
MEASURE DESCRIPTION:	Surgical patients who received prophylactic antibiotics consistent with current guidelines
	(specific to each type of surgical procedure).
NQF #:	0529
MEASURE TITLE:	Prophylactic Antibiotics Discontinued Within 24 Hours After Surgery End Time
MEASURE DESCRIPTION:	Surgical patients whose prophylactic antibiotics were discontinued within 24 hours after
	Anesthesia End Time. The Society of Thoracic Surgeons (STS) Practice Guideline for
	Antibiotic Prophylaxis in Cardiac Surgery (2006) indicates that there is no reason to
	extend antibiotics beyond 48 hours for cardiac surgery and very explicitly states that
	antibiotics should not be extended beyond 48 hours even with tubes and drains in place
	for cardiac surgery.
NQF #:	0575
MEASURE TITLE:	Diabetes: HbA1c Control (<8%)
MEASURE DESCRIPTION:	The percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had
	HbA1c <8.0%.
	*Reviewed for substantive changes by the eMeasure Format Review Panel in 2010
NOT "	0000
NQF#:	0608
MEASURE TITLE:	Pregnant women that had HBsAg testing
MEASURE DESCRIPTION:	This measure reports compliance to hepatitis B surface antigen (HBsAg) testing during
	pregnancy; if the HBsAg test is absent, then the exclusion criteria (diagnosis of hepatitis
	B infection) is applied.
NQF#:	ACP-017-10
MEASURE TITLE:	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History
WEASURE TITLE.	of Adenomatous Polyps - Avoidance of Inappropriate Use
MEASURE DESCRIPTION:	Percentage of patients aged 18 years and older receiving a surveillance colonoscopy,
WEASURE DESCRIPTION.	with a history of a prior colonic polyp in previous colonoscopy findings who had a follow-
	up interval of 3 or more years since their last colonoscopy documented in the
	colonoscopy report.
	Colonoscopy report.
NQF #:	OT3-011-10
MEASURE TITLE:	Depression Remission at Twelve Months
MEASURE DESCRIPTION:	Adult patients age 18 and older with major depression or dysthymia and an initial PHQ-9
MEASONE DESCRIPTION.	score > 9 who demonstrate remission at twelve months defined as PHQ-9 score less
	than 5. This measure applies to both patients with newly diagnosed and existing
	depression whose current PHO-0 score indicates a need for treatment

depression whose current PHQ-9 score indicates a need for treatment.

NQF #:	OT3-012-10
MEASURE TITLE:	Depression Remission at Six Months
MEASURE DESCRIPTION:	Adult patients age 18 and older with major depression or dysthymia and an initial PHQ-9 score > 9 who demonstrate remission at six months defined as PHQ-9 score less than 5. This measure applies to both patients with newly diagnosed and existing depression whose current PHQ-9 score indicates a need for treatment.
NQF #:	OT3-022-10
MEASURE TITLE:	Depression Utilization of the PHQ-9 Tool
MEASURE DESCRIPTION:	Adult patients age 18 and older with the diagnosis of major depression or dysthymia who have a PHQ-9 tool administered at least once during a 4 month period in which there was a qualifying visit.